Elsevier

Neuroscience Letters

Volume 228, Issue 2, 6 June 1997, Pages 119-122
Neuroscience Letters

Regionally specific effects of haloperidol and clozapine on dopamine reuptake in the striatum

https://doi.org/10.1016/S0304-3940(97)00377-7Get rights and content

Abstract

This study examined the extent to which local application of the typical neuroleptic haloperidol (HAL) or the atypical neuroleptic clozapine (CLOZ) influences dopamine (DA) transporter function in the dorsal and ventral striatum. Using urethane-anesthetized rats, DA was pressure ejected and monitored with in vivo electrochemistry, into the dorsal and ventral striatum to establish regional baseline DA reuptake rates. Haloperidol or CLOZ (10 μM) was then applied, followed 5 min later by DA, in order to assess drug effects on DA reuptake rates. Haloperidol caused a 62% decrease in dorsal striatal DA reuptake rates while CLOZ had no effect on reuptake rates. Neither neuroleptic significantly altered DA reuptake rates in the ventral striatum. It is possible that HAL-induced decrease in DA reuptake in the sensorimotor striatum could be related to the motor side effect profile of this neuroleptic. Additional studies with other typical and atypical neuroleptics are needed to further evaluate the relationship between slowing of DA reuptake and the side effect potential of neuroleptic agents.

Section snippets

Acknowledgements

This research was supported by the F.M. Kirby Foundation. The authors thank Dr. T.I. Lidsky for providing helpful comments concerning this research.

References (24)

  • R.E. See et al.

    Subchronic administration of clozapine, but not haloperidol or metoclopramide, decreases dopamine D2 receptor messenger RNA levels in the nucleus accumbens and the caudate-putamen in rats

    Neuroscience

    (1996)
  • S.J. Boyson et al.

    Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum

    J. Pharmacol. Exp. Ther.

    (1988)
  • Cited by (29)

    • Striatal dopamine neurotransmission: Regulation of release and uptake

      2016, Basal Ganglia
      Citation Excerpt :

      Activation of several GPCRs can also regulate DAT function [388,389]. Studies using acute administration of agonists and antagonists of the D2 receptor have established a positive regulation of DAT activity and surface expression by D2 DA autoreceptor activation in vivo and in vitro [410–416]. D2 receptor-dependent upregulation of DAT activity may involve G-proteins, ERK1/2 and PKA [411,415,417], with inhibition of ERK1/2 leading to a decrease in DAT function and its cell-surface localization [418].

    • Regulation of Extracellular Dopamine: Release and Uptake

      2016, Handbook of Behavioral Neuroscience
      Citation Excerpt :

      Activation of several G-protein-coupled receptors can also regulate DAT function (Gulley and Zahniser, 2003; Schmitt and Reith, 2010). Most studies using acute administration of agonists and antagonists of the D2 receptor have established a positive regulation of DAT activity and surface expression by D2 autoreceptors in vivo and in vitro (Batchelor and Schenk, 1998; Cass and Gerhardt, 1994; Mayfield and Zahniser, 2001; Meiergerd et al., 1993; Rothblat and Schneider, 1997; Wieczorek and Kruk, 1994; Wu et al., 2002). D2-receptor-dependent upregulation of DAT activity may involve G-proteins, ERK1/2, and PKA (Batchelor and Schenk, 1998; Bolan et al., 2007; Mayfield and Zahniser, 2001), with inhibition of ERK1/2 leading to a decrease in DAT function and its cell-surface localization (Moron et al., 2003).

    • Regulation of striatal dopamine release by presynaptic auto- and heteroreceptors

      2012, Basal Ganglia
      Citation Excerpt :

      There are multiple pathways or mechanisms at different time scales to achieve this. Activation of dopamine autoreceptors can decrease release by inhibiting dopamine synthesis and enhancing dopamine reuptake by the dopamine transporter as well as regulating vesicular monoamine transporter (VMAT2) expression [4,14,15]. These are slow processes that may last for minutes to hours.

    • Regulation of Extracellular Dopamine: Release and Reuptake

      2010, Handbook of Behavioral Neuroscience
      Citation Excerpt :

      However, even in these regions, pharmacological inhibition of DAT strongly slows the clearance of released dopamine (Mundorf et al., 2001). In vivo studies (Cass and Gerhardt, 1994; Rothblat and Schneider, 1997) show that D2 antagonists slow the clearance of exogenously applied dopamine. Moreover, D2 antagonists decrease the rate of elimination of endogenous dopamine released in vivo by electrical stimulation (Benoit-Marand et al., 2001; Wu et al., 2002).

    View all citing articles on Scopus
    View full text